EMEA-001006-PIP03-16

Key facts

Invented name
  • Vargatef
  • Ofev
  • Vargatef; Ofev
Active substance
nintedanib
Therapeutic area
Oncology
Decision number
P/0124/2017
PIP number
EMEA-001006-PIP03-16
Pharmaceutical form(s)
  • Capsule
  • Capsule (soft)
Condition(s) / indication(s)
  • Treatment of lung carcinoma (small cell and non-small cell carcinoma)
  • Treatment of mesothelioma
Route(s) of administration
Oral use
Contact for public enquiries
Boehringer Ingelheim International GmbH

Tel. +49 6132778271
E-mail: paediatrics@boehringer-ingelheim.com

 

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating